左诗意  博士

办公地址：广州国际校区C1-a805 电子邮件:zuoshiyi@aliyun.com

2025-至今  华南理工大学生物医学科学与工程学院  博士后

2021-2025  沈阳药科大学药剂学  博士

2024-2025  阿德莱德大学（澳洲）  化学工程  公派留学

2018-2021  沈阳药科大学药剂学  硕士

2014-2018  沈阳药科大学药物制剂  学士

纳米递送载体、肿瘤免疫治疗、抗体药物

本人在硕博期间主要从事抗肿瘤药物递送、小分子前药自组装纳米技术和核酸药物递送等方面的研究。以第一作者和共同第一作者身份在Cell Reports Medicine和Small等期刊发表9篇SCI论文，获得授权发明专利5项。

个人代表论文

1. Zuo S, Liu T, Li L, etal. Tetrasulfide bond boosts the anti-tumor efficacy of dimeric prodrugnanoassemblies. Cell Reports Medicine, 2024, 5(3):101432.

2. Zuo S*, Sun B*, YangY, et al. Probing the superiority of diselenium bond on docetaxel dimeric prodrugnanoassemblies: small roles taking big responsibilities. Small, 2020,16, 2005039.

3. Zuo S, Wang Q, Su X,et al. Bioinspired prodrug nanoassemblies with dual PEGylation and membrane-coatingstrategies. Nano Research, 2025, 10.26599/NR.2025.94907570.

4. Zuo S, Song J, ZhangJ, et al. Nano-immunotherapy: the application of nanotechnology in each stageof cancer cellular immunity. Theranostics, 2021, 11(15):7471-7487.

5. Yang Y*, Zuo S*, ZhangJ, et al. Prodrug nanoassemblies bridged by Mono-/Di-/Tri-sulfide bonds. NanoToday, 2022, 44:101480.

6. Xu H*, Zuo S*, Wang D,et al. Cabazitaxel prodrug nanoassemblies with branched chain modifications. Journalof Controlled Release, 2023, 360:784–795.

7. Gao Y*, Zuo S*, Li L,et al. The length of disulfide bond-containing linkages impacts the oral absorptionand antitumor activity of paclitaxel prodrugs-loaded nanoemulsions. Nanoscale,2021,13, 10536-10543.

8. Yu Y*, Zuo S*, SongJ*, et al. pH-sensitive doxorubicin-fatty acid prodrugs. Nano Research,2024, 17(6):5491–5500.

9. Wang Q*, Zuo S*, ZhengS, et al. Branched module-modified SN38 prodrug nanoassemblies. NanoResearch, 2025, 18(1):94907011–14.